Nov 25, 2025 – It is with profound sadness that we share the passing of our friend and colleague, Dr. Brian Feagan. Our hearts are with his family during this incredibly difficult time.

Brian’s career was defined by exceptional achievement, unwavering curiosity, and a deep commitment to improving the lives of patients with Inflammatory Bowel Disease. After completing a BSc in Bacteriology & Immunology, he earned a Master’s in Medical Microbiology from the London School of Hygiene and Tropical Medicine, followed by his MD at Western University. He went on to receive Royal College certifications in Internal Medicine and Gastroenterology and completed advanced training in Epidemiology and Biostatistics at McMaster University.

As Principal Investigator on dozens of clinical trials and author of more than 500 publications, cited over 40,000 times, Brian stood among the top 1% of cited scientists globally.

His work fundamentally shaped modern IBD research and treatment. From early methotrexate studies to the pivotal phase 2 trials of vedolizumab, including administering the very first dose in London, Ontario, Brian’s leadership changed the care landscape for millions around the world. He was also the visionary behind central reading in clinical trials, a practice that has since become a global standard.

Brian’s impact on our organization is immeasurable. Beginning in 1997 as Director of Robarts Clinical Trials at the Robarts Research Institute, he led the transformation that ultimately evolved into Alimentiv. His strategic leadership not only expanded our scientific reach worldwide but also inspired the creation of the Alimentiv Health Trust, which continues to anchor our mission, values, and independence today.

While Brian was known for his sharp intellect and direct manner, those who worked closely with him also saw his deep generosity and quiet kindness. He invested in people, championed talent, and shared his curiosity widely, whether offering career-shaping guidance, gardening tips, or recommendations for places worth exploring. His encouragement and support shaped the careers of countless trainees, colleagues, investigators, and partners across academic, clinical and industry committees.

At the heart of Brian’s work was a simple motivation: ensuring that patients had access to the best possible care. His compassion for those living with IBD fueled his relentless pursuit of scientific rigor, innovation, and evidence-based medicine.

We will deeply miss Brian’s drive, intellect, and the passion he brought to everything he pursued. His legacy lives on in the science he advanced, the teams he built, and the patients around the world whose lives have been improved because of his work.

We invite friends, colleagues, and collaborators to share a tribute in memory of Dr. Brian Feagan, whose impact on our community and the field of GI research will be profoundly missed.

Donations in Brian’s memory can be made to the Crohn’s & Colitis Canada.